Bloomberg News

Kamada Rises to Six-Month High on Juvenile Diabetes Drug Trials

April 16, 2012

Kamada Ltd. (KMDA) rose to the highest level in almost six months after the biopharmaceutical company said initial results from Phase I and II clinical trials on a drug to treat juvenile diabetes showed a positive trend.

The shares advanced 3.8 percent to 24.19 shekels at 10:48 a.m. in Tel Aviv, the highest level since Oct. 27, giving the Nes Ziona-based company a market value of 668 million shekels ($178 million).

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net


Tim Cook's Reboot
LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus